City Therapeutics Announces Submission of Clinical Trial Application for CITY-FXI, an Investigational RNAi Therapeutic for the Treatment of Thromboembolic Diseases
City Therapeutics, Inc., a biopharmaceutical company leading the future of RNA interference (RNAi)-based medicine, today announced the submission of a Clinical Trial Application (CTA) to the UK Medicines and Healthcare Products Regulatory Agency (MHRA) to initiate a Phase 1 study of CITY-FXI, an investigational RNAi therapeutic targeting Factor XI (FXI). CITY-FXI is intended to be a safe and effective anticoagulant with reduced bleeding risk compared to today’s standard of care therapies.
City Therapeutics Expands Executive Team and Board of Directors
City Therapeutics, Inc., a privately held biopharmaceutical company leading the future of RNA interference (RNAi)-based medicine, today announced additions to its executive team and board of directors. Baisong Mei, M.D., Ph.D., joins as newly appointed chief medical officer and Anna O’Driscoll joins as chief human resources officer. In addition, Sara Nochur, Ph.D., has been appointed as an independent board member.
City Therapeutics Announces Strategic Collaboration with Bausch + Lomb to Develop a Novel RNAi-Based Treatment for Geographic Atrophy
City Therapeutics, Inc., a privately held biopharmaceutical company leading the future of RNA interference (RNAi)-based medicine, today announced that it has entered into a strategic collaboration with global eye health leader Bausch + Lomb focused on the development of a novel therapy for the treatment of retinal diseases including geographic atrophy (GA), an advanced form of age-related macular degeneration (AMD) that causes irreversible vision loss.
City Therapeutics Appoints Andy Orth as Chief Executive Officer
City Therapeutics, Inc., a biopharmaceutical company leading the future of RNA interference (RNAi)-based medicine, today announced the appointment of Andrew “Andy” Orth as chief executive officer and director. Mr. Orth is an accomplished executive with more than 25 years of experience in biopharmaceutical research and development and commercialization, most recently as chief commercial officer of Krystal Biotech and earlier at Alnylam Pharmaceuticals.
City Therapeutics Launches with $135 Million Series A Financing to Lead the Future of RNAi-based Medicine
City Therapeutics, Inc. announced its launch today with a vision to lead the future of RNA interference (RNAi)-based medicine. City Therapeutics™ aims to harness next-generation engineering of small interfering RNAs (siRNAs) – the “trigger” molecules that mediate RNAi – to build a robust and sustainable product engine and expand the therapeutic reach of RNAi-based medicines. Led by executive chair John Maraganore, Ph.D., founding CEO of Alnylam Pharmaceuticals, Inc., the company has completed a $135 million Series A financing led by ARCH Venture Partners, with participation from other leading life sciences investors including Fidelity Management & Research Company, Invus, Slate Path Capital, Rock Springs Capital, Regeneron Ventures, AN Ventures and other undisclosed investors.
